Cargando…

The System Profile of Renal Drug Transporters in Tubulointerstitial Fibrosis Model and Consequent Effect on Pharmacokinetics

With the widespread clinical use of drug combinations, the incidence of drug–drug interactions (DDI) has significantly increased, accompanied by a variety of adverse reactions. Drug transporters play an important role in the development of DDI by affecting the elimination process of drugs in vivo, e...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Birui, Zhang, Yan, Huang, Baolin, Lin, Huiping, Zhou, Qiong, Wang, Yujue, Cai, Zheng, Liu, Menghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8838889/
https://www.ncbi.nlm.nih.gov/pubmed/35163972
http://dx.doi.org/10.3390/molecules27030704
_version_ 1784650233220694016
author Shi, Birui
Zhang, Yan
Huang, Baolin
Lin, Huiping
Zhou, Qiong
Wang, Yujue
Cai, Zheng
Liu, Menghua
author_facet Shi, Birui
Zhang, Yan
Huang, Baolin
Lin, Huiping
Zhou, Qiong
Wang, Yujue
Cai, Zheng
Liu, Menghua
author_sort Shi, Birui
collection PubMed
description With the widespread clinical use of drug combinations, the incidence of drug–drug interactions (DDI) has significantly increased, accompanied by a variety of adverse reactions. Drug transporters play an important role in the development of DDI by affecting the elimination process of drugs in vivo, especially in the pathological state. Tubulointerstitial fibrosis (TIF) is an inevitable pathway in the progression of chronic kidney disease (CKD) to end-stage renal disease. Here, the dynamic expression changes of eleven drug transporters in TIF kidney have been systematically investigated. Among them, the mRNA expressions of Oat1, Oat2, Oct1, Oct2, Oatp4C1 and Mate1 were down-regulated, while Oat3, Mrp2, Mrp4, Mdr1-α, Bcrp were up-regulated. Pearson correlation analysis was used to analyze the correlation between transporters and Creatinine (Cr), OCT2 and MATE1 showed a strong negative correlation with Cr. In contrast, Mdr1-α exhibited a strong positive correlation with Cr. In addition, the pharmacokinetics of cimetidine, ganciclovir, and digoxin, which were the classical substrates for OCT2, MATE1 and P-glycoprotein (P-gp), respectively, have been studied. These results reveal that changes in serum creatinine can indicate changes in drug transporters in the kidney, and thus affect the pharmacokinetics of its substrates, providing useful information for clinical use.
format Online
Article
Text
id pubmed-8838889
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88388892022-02-13 The System Profile of Renal Drug Transporters in Tubulointerstitial Fibrosis Model and Consequent Effect on Pharmacokinetics Shi, Birui Zhang, Yan Huang, Baolin Lin, Huiping Zhou, Qiong Wang, Yujue Cai, Zheng Liu, Menghua Molecules Article With the widespread clinical use of drug combinations, the incidence of drug–drug interactions (DDI) has significantly increased, accompanied by a variety of adverse reactions. Drug transporters play an important role in the development of DDI by affecting the elimination process of drugs in vivo, especially in the pathological state. Tubulointerstitial fibrosis (TIF) is an inevitable pathway in the progression of chronic kidney disease (CKD) to end-stage renal disease. Here, the dynamic expression changes of eleven drug transporters in TIF kidney have been systematically investigated. Among them, the mRNA expressions of Oat1, Oat2, Oct1, Oct2, Oatp4C1 and Mate1 were down-regulated, while Oat3, Mrp2, Mrp4, Mdr1-α, Bcrp were up-regulated. Pearson correlation analysis was used to analyze the correlation between transporters and Creatinine (Cr), OCT2 and MATE1 showed a strong negative correlation with Cr. In contrast, Mdr1-α exhibited a strong positive correlation with Cr. In addition, the pharmacokinetics of cimetidine, ganciclovir, and digoxin, which were the classical substrates for OCT2, MATE1 and P-glycoprotein (P-gp), respectively, have been studied. These results reveal that changes in serum creatinine can indicate changes in drug transporters in the kidney, and thus affect the pharmacokinetics of its substrates, providing useful information for clinical use. MDPI 2022-01-21 /pmc/articles/PMC8838889/ /pubmed/35163972 http://dx.doi.org/10.3390/molecules27030704 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Shi, Birui
Zhang, Yan
Huang, Baolin
Lin, Huiping
Zhou, Qiong
Wang, Yujue
Cai, Zheng
Liu, Menghua
The System Profile of Renal Drug Transporters in Tubulointerstitial Fibrosis Model and Consequent Effect on Pharmacokinetics
title The System Profile of Renal Drug Transporters in Tubulointerstitial Fibrosis Model and Consequent Effect on Pharmacokinetics
title_full The System Profile of Renal Drug Transporters in Tubulointerstitial Fibrosis Model and Consequent Effect on Pharmacokinetics
title_fullStr The System Profile of Renal Drug Transporters in Tubulointerstitial Fibrosis Model and Consequent Effect on Pharmacokinetics
title_full_unstemmed The System Profile of Renal Drug Transporters in Tubulointerstitial Fibrosis Model and Consequent Effect on Pharmacokinetics
title_short The System Profile of Renal Drug Transporters in Tubulointerstitial Fibrosis Model and Consequent Effect on Pharmacokinetics
title_sort system profile of renal drug transporters in tubulointerstitial fibrosis model and consequent effect on pharmacokinetics
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8838889/
https://www.ncbi.nlm.nih.gov/pubmed/35163972
http://dx.doi.org/10.3390/molecules27030704
work_keys_str_mv AT shibirui thesystemprofileofrenaldrugtransportersintubulointerstitialfibrosismodelandconsequenteffectonpharmacokinetics
AT zhangyan thesystemprofileofrenaldrugtransportersintubulointerstitialfibrosismodelandconsequenteffectonpharmacokinetics
AT huangbaolin thesystemprofileofrenaldrugtransportersintubulointerstitialfibrosismodelandconsequenteffectonpharmacokinetics
AT linhuiping thesystemprofileofrenaldrugtransportersintubulointerstitialfibrosismodelandconsequenteffectonpharmacokinetics
AT zhouqiong thesystemprofileofrenaldrugtransportersintubulointerstitialfibrosismodelandconsequenteffectonpharmacokinetics
AT wangyujue thesystemprofileofrenaldrugtransportersintubulointerstitialfibrosismodelandconsequenteffectonpharmacokinetics
AT caizheng thesystemprofileofrenaldrugtransportersintubulointerstitialfibrosismodelandconsequenteffectonpharmacokinetics
AT liumenghua thesystemprofileofrenaldrugtransportersintubulointerstitialfibrosismodelandconsequenteffectonpharmacokinetics
AT shibirui systemprofileofrenaldrugtransportersintubulointerstitialfibrosismodelandconsequenteffectonpharmacokinetics
AT zhangyan systemprofileofrenaldrugtransportersintubulointerstitialfibrosismodelandconsequenteffectonpharmacokinetics
AT huangbaolin systemprofileofrenaldrugtransportersintubulointerstitialfibrosismodelandconsequenteffectonpharmacokinetics
AT linhuiping systemprofileofrenaldrugtransportersintubulointerstitialfibrosismodelandconsequenteffectonpharmacokinetics
AT zhouqiong systemprofileofrenaldrugtransportersintubulointerstitialfibrosismodelandconsequenteffectonpharmacokinetics
AT wangyujue systemprofileofrenaldrugtransportersintubulointerstitialfibrosismodelandconsequenteffectonpharmacokinetics
AT caizheng systemprofileofrenaldrugtransportersintubulointerstitialfibrosismodelandconsequenteffectonpharmacokinetics
AT liumenghua systemprofileofrenaldrugtransportersintubulointerstitialfibrosismodelandconsequenteffectonpharmacokinetics